scholarly journals COVID‐19 Spurs Transplant Vaccination Policy

2021 ◽  
Vol 21 (12) ◽  
pp. 3817-3818
Author(s):  
Lara C. Pullen
Keyword(s):  
Vaccination Policy

Explore the Possible Impact of BCG Vaccination Policy on the Morbidity, Mortality, and Recovery Rates due to COVID-19 Infection. (Preprint)

2020 ◽  
Author(s):  
Yue-Cune Chang
Keyword(s):  
Odds Ratio ◽  
Randomized Clinical Trials ◽  
Vaccination Policy ◽  
Bacille Calmette Guerin ◽  
Recovery Rates ◽  
Bcg Vaccination ◽  
The World ◽  
New Form ◽  
The Relationship ◽  
Disease Specific

BACKGROUND The Coronavirus Disease-19 (COVID-19) is the new form of an acute infectious respiratory disease and has quickly spread over most continents in the world. Recently, it has been shown that Bacille Calmette-Guerin (BCG) might protect against COVID-19. This study aims to investigate the possible correlation between BCG vaccination and morbidity/mortality/recovery rate associated with COVID-19 infection. OBJECTIVE Our findings confirm that the BCG vaccination might protect against COVID-19 virus infection. METHODS Data of COVID-19 confirmed cases, deaths, recoveries, and population were obtained from https://www.worldometers.info/coronavirus/ (Accessed on 12 June, 2020). To have meaningful comparisons among countries’ mortality and recovery rates, we only choose those countries with COVID-19 infected cases at least 200. The Poisson regression and logistic regression were used to explore the relationship between BCG vaccination and morbidity, mortality and recovery rates. RESULTS Among those 158 countries with at least 200 COVID-19 infected cases, there were 141 countries with BCG vaccination information available. The adjusted rates ratio of COVID-19 confirmed cases for Current BCG vaccination vs. non-Current BCG vaccination was 0.339 (with 95% CI= (0.338,0.340)). Moreover, the adjusted odds ratio (OR) of death and recovery after coronavirus infected for Current BCG vaccination vs. non-Current BCG vaccination were 0.258 (with 95% CI= (0.254,0.261)) and 2.151 (with 95% CI= (2.140,2.163)), respectively. CONCLUSIONS That data in this study show the BCG might provide the protection against COVID-19, with consequent less COVID-19 infection and deaths and more rapid recovery. BCG vaccine might bridge the gap before the disease-specific vaccine is developed, but this hypothesis needs to be further tested in rigorous randomized clinical trials. INTERNATIONAL REGISTERED REPORT RR2-https://doi.org/10.1101/2020.06.14.20131268

scholarly journals COVID-19 Vaccination Willingness among Chinese Adults under the Free Vaccination Policy

Vaccines ◽  
2021 ◽  
Vol 9 (3) ◽  
pp. 292
Author(s):  
Rugang Liu ◽  
Yuxun Zhang ◽  
Stephen Nicholas ◽  
Anli Leng ◽  
Elizabeth Maitland ◽  
...  
Keyword(s):  
Regression Models ◽  
Medical Insurance ◽  
Vaccine Safety ◽  
Decision Makers ◽  
Vaccination Policy ◽  
Chinese Adults ◽  
Logistic Regression Models ◽  
Ordered Logistic Regression ◽  
Professional Workers ◽  
Target Intervention

(1) Background: China will provide free coronavirus disease 2019 (COVID-19) vaccinations for the entire population. This study analyzed the COVID-19 vaccination willingness rate (VWR) and its determinants under China’s free vaccination policy compared to a paid vaccine. (2) Methods: Data on 2377 respondents were collected through a nationwide questionnaire survey. Multivariate ordered logistic regression models were specified to explore the correlation between the VWR and its determinants. (3) Results: China’s free vaccination policy for COVID-19 increased the VWR from 73.62% to 82.25% of the respondents. Concerns about the safety and side-effects were the primary reason for participants’ unwillingness to be vaccinated against COVID-19. Age, medical insurance and vaccine safety were significant determinants of the COVID-19 VWR for both the paid and free vaccine. Income, occupation and vaccine effectiveness were significant determinants of the COVID-19 VWR for the free vaccine. (4) Conclusions: Free vaccinations increased the COVID-19 VWR significantly. People over the age of 58 and without medical insurance should be treated as the target intervention population for improving the COVID-19 VWR. Contrary to previous research, high-income groups and professional workers should be intervention targets to improve the COVID-19 VWR. Strengthening nationwide publicity and education on COVID-19 vaccine safety and effectiveness are recommended policies for decision-makers.

scholarly journals A Call for a Reform of the Influenza Immunization Program in Mexico: Epidemiologic and Economic Evidence for Decision Making

Vaccines ◽  
2021 ◽  
Vol 9 (3) ◽  
pp. 286
Author(s):  
Roberto Tapia-Conyer ◽  
Miguel Betancourt-Cravioto ◽  
Alejandra Montoya ◽  
Jorge Abelardo Falcón-Lezama ◽  
Myrna María Alfaro-Cortes ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Influenza Vaccination ◽  
Vaccination Coverage ◽  
Decision Analytic Model ◽  
Limited Information ◽  
Vaccination Policy ◽  
Cross Sectional ◽  
Influenza Case ◽  
One Year ◽  
Effectiveness Studies

Limited information is available to determine the effectiveness of Mexico’s national influenza vaccination guidelines and inform policy updates. We aim to propose reforms to current influenza vaccination policies based on our analysis of cost-effectiveness studies. This cross-sectional epidemiological study used influenza case, death, discharge and hospitalization data from several influenza seasons and applied a one-year decision-analytic model to assess cost-effectiveness. The primary health outcome was influenza cases avoided; secondary health outcomes were influenza-related events associated with case reduction. By increasing vaccination coverage to 75% in the population aged 12–49 years with risk factors (diabetes, high blood pressure, morbid obesity, chronic renal failure, asthma, pregnancy), and expanding universal vaccination coverage to school-aged children (5–11 years) and adults aged 50–59 years, 7142–671,461 influenza cases; 1–15 deaths; 7615–262,812 healthcare visits; 2886–154,143 emergency room admissions and 2891–97,637 hospitalizations could be prevented (ranges correspond to separate age and risk factor groups), with a net annual savings of 3.90 to 111.99 million USD. Such changes to the current vaccination policy could potentially result in significant economic and health benefits. These data could be used to inform the revision of a vaccination policy in Mexico with substantial social value.

scholarly journals The Safety of COVID-19 Vaccinations—We Should Rethink the Policy

Vaccines ◽  
2021 ◽  
Vol 9 (7) ◽  
pp. 693
Author(s):  
Harald Walach ◽  
Rainer J. Klement ◽  
Wouter Aukema
Keyword(s):  
Side Effects ◽  
Confidence Interval ◽  
Field Study ◽  
Adverse Reactions ◽  
Safety Data ◽  
European Medicines Agency ◽  
Point Estimate ◽  
Drug Reactions ◽  
Vaccination Policy ◽  
Risks And Benefits

Background: COVID-19 vaccines have had expedited reviews without sufficient safety data. We wanted to compare risks and benefits. Method: We calculated the number needed to vaccinate (NNTV) from a large Israeli field study to prevent one death. We accessed the Adverse Drug Reactions (ADR) database of the European Medicines Agency and of the Dutch National Register (lareb.nl) to extract the number of cases reporting severe side effects and the number of cases with fatal side effects. Result: The NNTV is between 200–700 to prevent one case of COVID-19 for the mRNA vaccine marketed by Pfizer, while the NNTV to prevent one death is between 9000 and 50,000 (95% confidence interval), with 16,000 as a point estimate. The number of cases experiencing adverse reactions has been reported to be 700 per 100,000 vaccinations. Currently, we see 16 serious side effects per 100,000 vaccinations, and the number of fatal side effects is at 4.11/100,000 vaccinations. For three deaths prevented by vaccination we have to accept two inflicted by vaccination. Conclusions: This lack of clear benefit should cause governments to rethink their vaccination policy.

MATERNAL RUBELLA AT ST. THOMAS' HOSPITAL: IS THERE A NEED TO CHANGE BRITISH VACCINATION POLICY?

The Lancet ◽  
1978 ◽  
Vol 312 (8103) ◽  
pp. 1298-1300 ◽  
Author(s):  
P.N. Goldwater ◽  
J.R. Quiney ◽  
J.E. Banatvala
Keyword(s):  
Vaccination Policy

MEASLES CONTROL IN YAOUNDE: JUSTIFICATION OF A ONE DOSE, NINE MONTH MINIMUM AGE VACCINATION POLICY IN TROPICAL AFRICA

The Lancet ◽  
1983 ◽  
Vol 322 (8365-8366) ◽  
pp. 1470-1472 ◽  
Author(s):  
DavidL. Heymann ◽  
KevinR. Murphy ◽  
Georges Kesseng Mayben ◽  
Bernard Guyer ◽  
StanleyO. Foster
Keyword(s):  
Vaccination Policy ◽  
Tropical Africa ◽  
Minimum Age

scholarly journals Measles and Rubella during COVID-19 Pandemic: Future Challenges in Japan

2020 ◽  
Vol 18 (1) ◽  
pp. 9
Author(s):  
Kazuki Shimizu ◽  
Ayaka Teshima ◽  
Hiromi Mase
Keyword(s):  
Preventive Measures ◽  
Global Scale ◽  
Childhood Vaccination ◽  
Personal Hygiene ◽  
Vaccination Policy ◽  
Good Opportunity ◽  
Routine Childhood ◽  
Future Challenges ◽  
Closing The Gap ◽  
Epidemiological Trends

The coronavirus disease 2019 (COVID-19) pandemic has significantly impacted essential health services. Simultaneously, it has created opportunities for citizens to raise awareness of personal hygiene, mask wearing, and other preventive measures. This brief report aims to clarify the epidemiological trends of measles and rubella in Japan and to explore future challenges for controlling these diseases during and after the COVID-19 pandemic. Although Japan eliminated measles in 2015, the number of measles patients has gradually increased since then, and reached 744 in 2019. In the 2010s, Japan experienced two large rubella epidemics, and the majority of the patients were reported in Tokyo and other metropolitan areas. While the transmission of measles and rubella seems to be suppressed during the COVID-19 pandemic, closing the gap in routine childhood vaccination will be challenging in any country. Moreover, supplementary immunization campaigns for adults have also been disrupted, and they must be invigorated. While the pandemic has a devastating effect on a global scale, it should be utilized as a good opportunity to regain faith in vaccines, implement an evidence-based vaccination policy, and strengthen international cooperation.

Sign in / Sign up

Export Citation Format

Share Document